Current and Future Immunomodulation Strategies to Restore Tolerance in Autoimmune Diseases
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Autoimmune diseases reflect a breakdown in self-tolerance that results from defects in thymic deletion of potentially autoreactive T cells (central tolerance) and in T-cell intrinsic and extrinsic mechanisms that normally control potentially autoreactive T cells in the periphery (peripheral tolerance). The mechanisms leading to autoimmune diseases are multifactorial and depend on a complex combination of genetic, epigenetic, molecular, and cellular elements that result in pathogenic inflammatory responses in peripheral tissues driven by self-antigen-specific T cells. In this article, we describe the different checkpoints of tolerance that are defective in autoimmune diseases as well as specific events in the autoimmune response which represent therapeutic opportunities to restore long-term tolerance in autoimmune diseases. We present evidence for the role of different pathways in animal models and the therapeutic strategies targeting these pathways in clinical trials in autoimmune diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623 · cited 1×
“Phase II and III clinical trials in RA, MS, and T1D have shown promising results and a potentially tolerogenic effect of rituximab as evidenced by improvement of disease for almost a year with a short-course treatment with rituximab (Edwards et al. 2004; Hauser et al. 2008; Pescovitz et al. 2009).”
BackgroundCD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606 · cited 1×
“CD4þCD25þCD127lo/ – Tregs will be purified from T1D patients (Liu et al. 2006) and expanded in vitro using an optimized protocol (Putnam et al.”
MethodSelf-citationLymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Epidemiology and estimated population burden of selected autoimmune diseases in the United States
Jacobson, D. L., Gange, S. J., Rose, N. R., & Graham, N. M. H. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4412 · Cited by 1,667 · cited 2×
“Autoimmune diseases are debilitating conditions that affect a large and growing portion of the population ( 3%–5% in the United States) (Jacobson et al. 1997).”
BackgroundGenetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265 · cited 4×
“A number of autoantigens have been characterized in T1D patients, including insulin, GAD65, and IGRP (Bluestone et al. 2010).”
BackgroundInfluentialSelf-citationAnti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Self-citationInsulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093 · cited 1×
“Phase II and III clinical trials in RA, MS, and T1D have shown promising results and a potentially tolerogenic effect of rituximab as evidenced by improvement of disease for almost a year with a short-course treatment with rituximab (Edwards et al. 2004; Hauser et al. 2008; Pescovitz et al. 2009).”
BackgroundMultiple sclerosis: a complicated picture of autoimmunity
McFarland, H. F., & Martin, R. (2007) · Nature Immunology · doi:10.1038/ni1507 · Cited by 985 · cited 1×
“Finally, both CD4þ and CD8þ T cells have been shown to mediate autoimmune diseases, and the tissue damage inherent to autoimmunity can be mediated by a range of proinflammatory cytokines produced by innate cells or T cells (McFarland and Martin 2007; Bluestone et al. 2010).”
BackgroundEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction
Tang, Q., Adams, J. Y., Penaranda, C., Melli, K., Piaggio, E., Sgouroudis, E., Piccirillo, C. A., Salomon, B. L., & Bluestone, J. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.016 · Cited by 729
Self-citationOrban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease
Dominguez-Villar, M., Baecher-Allan, C. M., & Hafler, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2389 · Cited by 526
Couri, C. E. B. (2009) · JAMA · doi:10.1001/jama.2009.470 · Cited by 449
Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes
McClymont, S. A., Putnam, A. L., Lee, M. R., Esensten, J. H., Liu, W., Hulme, M. A., Hoffmüller, U., Baron, U., Olek, S., Bluestone, J. A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003099 · Cited by 428
Self-citationNäntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Wherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60895-7 · Cited by 371
GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
Ludvigsson, J., Krisky, D., Casas, R., Battelino, T., Castaño, L., Greening, J., Kordonouri, O., Otonkoski, T., Pozzilli, P., Robert, J.-J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107096 · Cited by 340 · cited 1×
“Antigen therapy using alum-formulated GAD65 (GAD-alum) in newly diagnosed T1D patients was recently shown in a phase III trial to have no effect on the decline in stimulated C-peptide levels or any other secondary outcome despite some encouraging results in previous phase II trials (Wherrett et al. 2011; Ludvigsson et…”
ResultMasteller, E. L., Warner, M. R., Tang, Q., Tarbell, K. V., McDevitt, H., & Bluestone, J. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.3053 · Cited by 260
Self-citationHerold, K. C., Gitelman, S., Greenbaum, C., Puck, J., Hagopian, W., Gottlieb, P., Sayre, P., Bianchine, P., Wong, E., Seyfert-Margolis, V., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.04.007 · Cited by 219
Self-citationVendrame, F., Pileggi, A., Laughlin, E., Allende, G., Martin-Pagola, A., Molano, R. D., Diamantopoulos, S., Standifer, N., Geubtner, K., Falk, B. A., et al. (2010) · Diabetes · doi:10.2337/db09-0498 · Cited by 215
Walter, M., Philotheou, A., Bonnici, F., Ziegler, A.-G., Jimenez, R., & on behalf of the NBI-6024 Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0449 · Cited by 119 · cited 1×
“Several phase I and II trials were performed in new-onset diabetic patients using oral insulin or NBI-6024, an APL for the dominant 9–23 insulin B chain epitope, with no clinical efficacy (Chaillous 2000; Walter et al. 2009).”
MethodMaki, T., Gottschalk, R., Ogawa, N., & Monaco, A. P. (2005) · Transplantation · doi:10.1097/01.tp.0000161220.87548.ee · Cited by 68 · cited 1×
“attenuated disease in NOD mice, EAE, collageninduced arthritis, and colitis (Webb et al. 2004; Maki et al. 2005).”
Background
Cited by
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
T-Cell Tolerance: Central and Peripheral
Xing, Y., & Hogquist, K. A. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006957 · Cited by 576
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408686111 · Cited by 441
“Experimental approaches have included oral administration of antigen, high dose tolerance, and the use of altered peptide ligands (8).”
InfluentialNanotechnology for protein delivery: Overview and perspectives
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.012 · Cited by 410
“Antigen-specific, immune-tolerogenic therapies hold considerable promise for the treatment of allergic asthma, life-threatening food allergies, and autoimmune disease [89].”
BackgroundMesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells
Najar, M., Raicevic, G., Fayyad-Kazan, H., Bron, D., Toungouz, M., & Lagneaux, L. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2015.10.011 · Cited by 267
Metadata
- Authors
- Bluestone, J. A., & Bour-Jordan, H.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-11-01
- Volume
- 4
- Issue
- 11
- Pages
- a007542-a007542
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2123769527
- Cited by
- 66
- References
- 25
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.